Treatment virtually changed the face of medical aesthetics
Allergan, today announced that its flagship medical aesthetic brand, BOTOX® (Botulinum Toxin A), marks its 10th year this week since it received approval from the U.S. Food and Drug Administration’s (FDA) to improve the look of moderate to severe frown lines between the eyebrows in patients age 18-65.
“When approved by the FDA in 2002, BOTOX® changed the way that physicians could treat patients who were interested in improving the appearance of their vertical frown lines between the brows,” Raghu Kumar, Managing Director at Allergan India Pvt Ltd.
“In India, we have seen the use of BOTOX®, as a non surgical medical aesthetic procedure increase over the years. BOTOX® gave patients a new way to look refreshed and rejuvenated in a predictable and effective manner. It virtually changed the face of medical aesthetic treatments,” he added.
Worldwide BOTOX® has become very popular and the number of patients, considering talking to their doctor about treatment has more than quadrupled to 5.8 million since 2002. 
BOTOX® secured its first US FDA approval more than 22 years ago as a treatment for two rare eye muscle disorders, making it the first product of its kind approved in the world.
In India, BOTOX® was approved for the treatment of hyper kinetic facial lines like glabellar lines (lines that appear between the eye brows when you frown) in 2006. Today it is widely used in medical aesthetic clinics across the country.
In 2011, total BOTOX® sales, covering both its therapeutic and aesthetic uses, was nearly $ 1.6 billion globally increasing by 12.4 percent from the previous year.
Dr. Vandana Chatrath, Dermatologist, New Delhi “BOTOX®, has dramatically changed our ability to treat patients by giving them an effective option to treat the appearance of moderate to severe vertical frown lines with a minimally invasive procedure. The art and science of facial aesthetics reached new heights with BOTOX®. BOTOX® has become more accepted by the public, and this treatment has brought more patients into aesthetic practices to learn about other treatments available.”
“The FDA approval of BOTOX® enhanced the practice of plastic surgery by providing plastic surgeons with a new treatment option for patients seeking to reduce the appearance of vertical frown lines between the eyebrows,” said Dr. KM Kapoor, Plastic Surgeon, Chandigarh.
In the decade since BOTOX® was approved, aesthetic specialty physicians – which include dermatologists, oculoplastic surgeons and facial plastic surgeons – have developed extensive experience in the art and science of administering BOTOX® to yield predictable results for their patients. These physicians have performed approximately 11 million BOTOX® treatment sessions in the US since 2002 and have also contributed to the extensive clinical database demonstrating the safety and efficacy of the drug.